DR. ANNE-MARIE DULIEGE, M.D., M.S.
Medical Practice at Welch Rd, Palo Alto, CA
License number
California A49992
Category
Medical Practice
Type
Adolescent Medicine
Address
Address
725 Welch Rd, Palo Alto, CA 94304
Phone
(650) 812-8727
(650) 424-0260 (Fax)
(650) 424-0260 (Fax)
Professional information
Chief Medical Officer And Head Of Research &Amp; Clinical Development At Affymax
Position:
Chief Medical Officer and Head of Research & Clinical Development at Affymax, Board Member at California Institute for Regenerative Medicine (CIRM), Board Member at BayBio
Location:
San Francisco Bay Area
Industry:
Biotechnology
Work:
Affymax
- Palo Alto, CA since Jul 2004
-
Chief Medical Officer and Head of Research & Clinical Development
California Institute for Regenerative Medicine (CIRM)
since Oct 2012
-
Board Member
BayBio
since Nov 2012
-
Board Member
Chiron Corporation
- Emeryville, CA 1992 - 2004
-
Sr Medical Director
Genentech
- South San Francisco, CA 1990 - 1992
-
Sr Research Physician
Education:
UCSF 1990 - 1991
Residency in Pediatrics required to obtain California Medical License Paris Medical School 1988 - 1989
Master of Science (MS), Biostatistics Harvard University School of Public Health 1987 - 1988
Master of Science (MS), Epidemiology Paris Medical School 1982 - 1987
Certification in Pediatrics Paris Medical School 1976 - 1982
Doctor of Medicine (MD)
Residency in Pediatrics required to obtain California Medical License Paris Medical School 1988 - 1989
Master of Science (MS), Biostatistics Harvard University School of Public Health 1987 - 1988
Master of Science (MS), Epidemiology Paris Medical School 1982 - 1987
Certification in Pediatrics Paris Medical School 1976 - 1982
Doctor of Medicine (MD)
Skills:
Clinical Development, Clinical Research, Infectious Diseases, Pharmaceutical Industry, Immunology, Clinical Protocols, Biotechnology, Medical Writing, Medical Affairs, Transfusion Medicine
Anne-Marie Duliege, Palo Alto CA
Specialties:
Adolescent Medicine Specialist
Address:
725 Welch Rd, Palo Alto, CA 94304
Dr. Anne-Marie Duliege, Palo Alto CA - MD (Doctor of Medicine)
Specialties:
Rheumatology
Address:
725 Welch Rd, Palo Alto 94304
(650) 812-8727 (Phone), (650) 424-0260 (Fax)
(650) 812-8727 (Phone), (650) 424-0260 (Fax)
Languages:
English
Education:
Medical School
Xavier Bichat University De Paris Vii /U.F.R. of Medicine
Xavier Bichat University De Paris Vii /U.F.R. of Medicine
Erythropoietin Receptor Peptide Formulations And Uses
US Patent:
2007010, May 10, 2007
Filed:
Jun 2, 2006
Appl. No.:
11/446593
Inventors:
Anne-Marie Duliege - Palo Alto CA, US
Richard Stead - Bellevue WA, US
Kerstin Leuther - Palo Alto CA, US
Kathryn Woodburn - Campbell CA, US
Robert Naso - Menlo Park CA, US
Richard Stead - Bellevue WA, US
Kerstin Leuther - Palo Alto CA, US
Kathryn Woodburn - Campbell CA, US
Robert Naso - Menlo Park CA, US
Assignee:
Affymax, Inc. - Palo Alto CA
International Classification:
A61K 38/48
US Classification:
424094640
Abstract:
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
Erythropoietin Receptor Peptide Formulations And Uses
US Patent:
8324159, Dec 4, 2012
Filed:
Jul 23, 2008
Appl. No.:
12/178583
Inventors:
Anne-Marie Duliege - Palo Alto CA, US
Richard Stead - Bellevue WA, US
Kerstin Leuther - San Jose CA, US
Kathryn Wynne Woodburn - Saratoga CA, US
Robert Barnett Naso - Menlo Park CA, US
Richard Stead - Bellevue WA, US
Kerstin Leuther - San Jose CA, US
Kathryn Wynne Woodburn - Saratoga CA, US
Robert Barnett Naso - Menlo Park CA, US
Assignee:
Affymax, Inc. - Palo Alto CA
International Classification:
A61K 38/16
US Classification:
514 77, 514 54, 514 135, 514 154, 514 214
Abstract:
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
Erythropoietin Receptor Peptide Formulations And Uses
US Patent:
7919461, Apr 5, 2011
Filed:
Jul 13, 2007
Appl. No.:
11/777500
Inventors:
Anne-Marie Duliege - Palo Alto CA, US
Richard Stead - Bellevue WA, US
Kerstin Leuther - San Jose CA, US
Kathryn Wynne Woodburn - Campbell CA, US
Robert Barnett Naso - Menlo Park CA, US
Richard Stead - Bellevue WA, US
Kerstin Leuther - San Jose CA, US
Kathryn Wynne Woodburn - Campbell CA, US
Robert Barnett Naso - Menlo Park CA, US
Assignee:
Affymax, Inc. - Palo Alto CA
International Classification:
A61K 38/16
US Classification:
514 12
Abstract:
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
Erythropoietin Receptor Peptide Formulations And Uses
US Patent:
7906485, Mar 15, 2011
Filed:
Jun 5, 2006
Appl. No.:
11/916416
Inventors:
Anne-Marie Duliege - Palo Alto CA, US
Richard Stead - Bellevue WA, US
Kerstin Leuther - San Jose CA, US
Kathryn Wynne Woodburn - Campbell CA, US
Robert Barnett Naso - Menlo Park CA, US
Richard Stead - Bellevue WA, US
Kerstin Leuther - San Jose CA, US
Kathryn Wynne Woodburn - Campbell CA, US
Robert Barnett Naso - Menlo Park CA, US
Assignee:
Affymax, Inc. - Palo Alto CA
International Classification:
A61K 38/10, A61K 38/16
US Classification:
514 135, 514 214
Abstract:
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production, including pure red cell aplasia (PRCA). Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
Erythropoietin Receptor Peptide Formulations And Uses
US Patent:
2009022, Sep 3, 2009
Filed:
Aug 21, 2008
Appl. No.:
12/195832
Inventors:
RICHARD STEAD - Bellevue WA, US
ANNE-MARIE DULIEGE - Palo Alto CA, US
ROBERT HONG CHOON LEONG - Redwood City CA, US
JULIA IWASHITA - Campbell CA, US
WILLIAM LANG - Mill Valley CA, US
MARK A. WEINBERG - Glenview IL, US
ANNE-MARIE DULIEGE - Palo Alto CA, US
ROBERT HONG CHOON LEONG - Redwood City CA, US
JULIA IWASHITA - Campbell CA, US
WILLIAM LANG - Mill Valley CA, US
MARK A. WEINBERG - Glenview IL, US
International Classification:
A61K 38/08, A61P 7/00
US Classification:
514 15
Abstract:
The present invention relates to novel uses of peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to methods of using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production, including chemotherapy induced anemia. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided. Also provided are kits and articles of manufacture comprising such compounds.
Treatment Of Anti-Erythropoietin Antibody-Mediated Disorders With Synthetic Peptide-Based Epo Receptor Agonists
US Patent:
2009020, Aug 20, 2009
Filed:
Feb 13, 2009
Appl. No.:
12/370761
Inventors:
Anne-Marie Duliege - Palo Alto CA, US
Peter J. Schatz - Cupertino CA, US
Richard Stead - Bellevue WA, US
Kathryn Wynne Woodburn - Saratoga CA, US
Peter J. Schatz - Cupertino CA, US
Richard Stead - Bellevue WA, US
Kathryn Wynne Woodburn - Saratoga CA, US
Assignee:
Affymax, Inc. - Palo Alto CA
International Classification:
A61K 38/12, A61P 7/00
US Classification:
514 11
Abstract:
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat or to prevent anti-erythropoietin (EPO) antibody-mediated disorders such as pure red cell aplasia (PRCA) that are characterized by anti-EPO antibodies. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.